<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="206660">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00398151</url>
  </required_header>
  <id_info>
    <org_study_id>0476-366</org_study_id>
    <secondary_id>2006_043</secondary_id>
    <nct_id>NCT00398151</nct_id>
  </id_info>
  <brief_title>To Evaluate the Inflammatory Markers in Adult Patients With Asthma Associated With Allergic Rhinitis Receiving Montelukast Therapy (0476-366)</brief_title>
  <official_title>An Open-Label Study to Evaluate the Inflammatory Markers in Adult Patients With Asthma Associated With Allergic Rhinitis Receiving Montelukast Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      To evaluate the changes in proinflammatory markers (ltd4 in urine) and eosinophil from
      peripheral blood after newly initiated montelukast therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ltd4 in urine and eosinophil from peripheral blood over 3 months of therapy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Asthma symptoms score throughout the study</measure>
  </secondary_outcome>
  <enrollment type="Actual">58</enrollment>
  <condition>Asthma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0476, montelukast sodium / Duration of Treatment: 12 Weeks</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Allergic rhinitis symptoms: sneezing, rhinorrhea, obstruction of the nasal passages,
             itchy nose and throat, and conjunctival

          -  Male or female outpatient 20 years of age and older

          -  Patients with the following signs and symptoms of asthma and allergic rhinitis:
             history of cough, wheezing, shortness of breath, positive methacholine
             bronchoprovocation test

        Exclusion Criteria:

          -  Active, acute or chronic, pulmonary disorder (besides asthma) documented by history,
             physical examination, or chest x-ray. history of anaphylactic or hypersensitive to
             study drug

          -  Requires oral, intravenous, or intramuscular corticosteroids on daily routine basis

          -  Started on immunotherapy within six months before the pre-study visit and/or the dose
             of immunotherapy is expected to change over the course of the study

          -  Treated with montelukast within 3 months before enrollment

          -  Unable to perform acceptable, reproducible spirometry and peak flow measurement

          -  Unresolved symptoms and signs of an upper respiratory tract infection (uri) within 2
             weeks prior to visit 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Taiwan</country>
  </removed_countries>
  <link>
    <url>http://www.merck.com/clinical-trials/policies-perspectives.html</url>
    <description>Click here to access a synopsis of the study results.</description>
  </link>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 13, 2016</lastchanged_date>
  <firstreceived_date>November 9, 2006</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
